CTRI/2020/05/025271
Completed
Phase 3
A Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Sponsor
- Cadila Pharmaceuticals Limited
- Enrollment
- 481
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. COVID\-19 positive patients with ordinal scale score of 3 with comorbid illness including diabetes mellitus, hypertension, chronic lung disease, immunocompromised status, active malignancy, chronic kidney disease, chronic liver disease, obesity (BMI \>25Kg/m2\), or subjects who have doubling of CRP compared to baseline or have Neutrophil\-to\-Lymphocyte Ratio ââ?°Â¥3\.5\.
- •2\. Patients of either gender, age ââ?°Â¥ 18 years at the time of enrollment.
- •3\. Female patients who are currently using reliable methods of contraception (barrier methods and intrauterine contraceptive device), with a negative urine pregnancy test during screening and agree to informed compliance of contraceptive method until at least 3 months post\-dosing.
- •4\. The patients must be able and willing to comply with the study protocol, available and willing to complete all the study assessments and must have signed an Informed Consent Form.
Exclusion Criteria
- •1\. Patient with ordinal scale of ââ?°Â¥4 at the time of hospital admission and randomization.
- •2\. Pregnant and / or lactating female patients.
- •3\. A family history of congenital or hereditary immunodeficiency.
- •4\. Any disease condition requiring ICU admission.
- •5\. History of dialysis, silicosis, solid organ transplantation such as renal or cardiac transplants, and disorders of the heart, or nervous system, or other metabolic inflammatory conditions, psychiatric, occupational problems that make it unlikely that the patients will comply with the protocol as determined by the investigator.
- •6\. History of administration of any immunoglobulins, any immunotherapy (antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use) and/or any blood products within the 3 months preceding study dosing, or planned future administrations during the study period.
- •7\. History of allergic reactions or anaphylaxis to Mw or its component.
- •8\. Presence of any severe systemic/autoimmune disorders as determined by medical history and/or physical examination at the time of screening, which in the judgment of the Investigator would compromise the patientââ?¬•s health or is likely to result in nonconformance to the protocol or a patientââ?¬•s ability to give written informed consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A randomized, controlled, double-blind, two-arm clinical trial to assess safety and efficacy of transcutaneous vagus nerve stimulation (t-VNS®) in patients with drug-resistant epilepsyG40EpilepsyDRKS00003689cerbomed GmbH77
Active, not recruiting
Not Applicable
A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of AVE0010 to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50 and not adequately controlled with metformin.Type II DiabetesMedDRA version: 11.1Level: LLTClassification code 10045242Term: <Manually entered code. Term in E.1.1>EUCTR2008-007334-22-DESanofi-Aventis Recherche & Développement300
Active, not recruiting
Phase 1
A Randomized, Double Blind, Two Arms, Controlled Phase I/II Safety and Efficacy Study on MesoCellA-Ortho Tissue Engineered Product Intraarticularly Administrated in Adult Patients with OsteoarthrosisEUCTR2019-005000-17-PLJagiellonian University200
Completed
Phase 2
To evaluate efficacy, safety and tolerability of two dose strengths of tacrolimus lipid suspension for injection rectally administered in adult patients with ulcerative colitisHealth Condition 1: K519- Ulcerative colitis, unspecifiedCTRI/2015/10/006252Intas Pharmaceuticals Ltd60
Completed
Not Applicable
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsPER-069-09sanofi-aventis Recherche & Development,